A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor	NCT ID:	NCT06004245
Trial Phases:	Phase I	Protocol IDs:	BP44474 (primary) NCI-2023-06836 2023-503170-20-00 2023-503170-20-01
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT06004245

Summary

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose
expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,
and preliminary anti-tumor activity of RO7589831 monotherapy, and in combination with
pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient
mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a
protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or
dMMR. By acting on WRN, RO7589831 may be able to block the growth of these types of
cancer.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.